Why Alkermes Stock Is Back on Investors’ Radar

Alkermes (ALKS) has drawn fresh attention after reporting 28.2% revenue growth, alongside upbeat analyst commentary on its treatments for addiction, schizophrenia, bipolar I disorder, and neurological conditions.

That backdrop, together with executive stock transactions and a scheduled appearance at a major healthcare investor conference, provides several new data points to consider if you are tracking Alkermes stock.

Alkermes’ recent 19.67% 1 month share price return and 51.52% 3 month share price return, alongside conference exposure and insider trading activity, point to building momentum on top of a 39.94% 1 year total shareholder return.

If this kind of renewed interest in biopharma has your attention, it could be a good moment to scan other opportunities in healthcare related AI using the 40 healthcare AI stocks

With Alkermes trading at $43.38 against an analyst price target of $45.44 and an intrinsic value estimate implying a larger discount, you have to ask whether there is still a buying opportunity here or whether the current price already reflects expectations for future growth.

Most Popular Narrative: 1.9% Undervalued

The most followed narrative pegs Alkermes’ fair value at $44.24, just above the recent $43.38 close, and links that gap to its expanding neuroscience and sleep portfolio.

Expanding demand and market penetration for proprietary neuroscience products, paired with commercial execution, are fueling top-line growth and increasing operating leverage. Diversified pipeline progress, margin expansion, and financial strength provide flexibility for pipeline acceleration, external growth, and sustained earnings while minimizing dilution risk.

Want to see what is baked into that valuation gap? The narrative leans on compound revenue growth, shifting margins, and a future earnings multiple usually reserved for faster growing sectors.

Result: Fair Value of $44.24 (UNDERVALUED)

However, this hinges on factors that could easily shift, including heavier R&D spending on the orexin program and Alkermes’ dependence on a concentrated product portfolio.

Another Lens On Alkermes’ Valuation

The earlier narrative leans on an intrinsic value of $95.63 from our DCF model, which frames Alkermes as trading at a large discount to future cash flow estimates. On plain earnings, though, the stock changes hands at a P/E of 47.3x, well above the US Biotechs industry at 16.4x, peers at 31.5x, and even its own fair ratio of 36.8x. That gap suggests investors may be paying a premium today, even if long term cash flow estimates point to upside. The key question is which signal you prioritize more right now.

Next Steps

Curious whether the mix of concerns and optimism around Alkermes lines up with your own risk tolerance and goals? Act while the data is fresh and weigh both sides by checking the 2 key rewards and 2 important warning signs

Ready to Hunt for Your Next Stock Idea?

If Alkermes has sharpened your focus, do not stop here. Use fresh data and filters to spot other stocks that fit what you are really looking for.

• Target resilience first by checking companies that clear strict risk checks through the 65 resilient stocks with low risk scores.
• Spot potential mispricing by scanning for quality businesses trading below intrinsic value using the 46 high quality undervalued stocks.
• Zero in on under the radar opportunities with strong fundamentals through the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.